Picture of the awards given at the AMILO conference

Happy anniversary AMILO!

MPELeave a comment

One of the MPE Spanish members, the Spanish Amyloidosis Association (AMILO), last month celebrated its fifth anniversary by recognising the support and help other organisations have given them during these five years. MPE is pleased and proud to receive this recognition from AMILO at such an important event for our member. Along with MPE, other important national and international organisations were awarded, like the Amyloidosis Alliance and the Spanish Society of Hematology, represented by its…

Job offer – Medical and Scientific officer

MPELeave a comment

Job Title: Medical and Scientific Officer Position Type: Mini-job Probation period: six months Location: Germany Gross salary: 520 € monthly (approximately 43 hours a month) Tasks and core responsibilities (non-exhaustive and subject to change depending on the needs of the organisation). As Medical and Scientific officer, you will work in the Medical Education and Scientific Engagement area. You will assist the Head of Medical Education and Scientific Engagement with the following activities:   European Myeloma and…

Volunteers of AMEN protesting outside the “Health Basket” Committee conference to include Daratumumab for NDMM patients (December 2021)

Daratumumab approved for first line treatment in Israel

MPE, MyelomaLeave a comment

Funding for Daratumumab was recently approved in Israel for the treatment of newly diagnosed multiple myeloma (NDMM) patients in first line treatment, in large part thanks to a strong collaboration between the MPE Israeli member, AMEN, with local haematologists and pharmaceutical companies in Israel.    “Health Basket” Each year, the Israel Ministry of Health nominates a Health Committee to discuss and recommend approval and extension for a new “health basket,” which includes all the services, medications, supplies,…

2022: Year in Review

MPELeave a comment

Myeloma Patients Europe’s (MPE) 2022 Year in Review is snapshot of the major accomplishments from the past year. In this report, you’ll read about MPE’s activities and key accomplishments to empower our members, educate the patient community, shape drug development, address gaps in patient evidence, and increase access to innovative treatments. We look forward to the continued growth and evolution of these initiatives in the years ahead as we continue our efforts to improve patient treatment, care,…

Horizon Europe research project looks to improve the affordability and sustainability of innovative health technologies

Access, MPE, NewsLeave a comment

  Starting in December 2022, the HORIZON-funded project ASCERTAIN (Affordability and Sustainability improvements through new pricing, Cost- Effectiveness and Reimbursement models to Appraise innovative health technologies) will address the need of patients, physicians, payers, regulators, and manufacturers to improve the affordability and accessibility to innovative health technologies (including pharmaceuticals) in Europe. Affording newly approved innovative health technologies (IHTs) is challenging in many health systems.

Join MPE’s webinar on Access Barriers to Clinical Trials in CEE Countries

Access, MPE, NewsLeave a comment

Myeloma Patient Europe (MPE) has been aware of the lack of clinical trials opening in many Central and Eastern European (CEE) countries, as well as inequalities in access with CEE countries for participating in ongoing trials. To gather data on, and further understand the access situation, MPE conducted research on barriers and facilitators to clinical trials, with a specific focus on CEE countries. The research was completed under the guidance of MPE members from across the region through its CEE…

Myeloma diagnosis can take over 5 months and require more than 4 medical consultations with more than 3 different specialists

Access, MPE, Myeloma, Patient evidenceLeave a comment

Brussels, 27 September 2022 – For some European myeloma patients, their diagnosis can take over 5 months, require more than 4 medical consultations and involve visits to at least 3 different medical specialists. These are some of the findings of pan-European research conducted by Myeloma Patients Europe (MPE) with the aim of exploring patient and doctor (haematologist) experiences of myeloma diagnosis. MPE ran a survey, and several focus groups and interviews, in which more than 600…